On-line Registration

Anthony Fyles, MD FRCPC

Anthony Fyles is the Department of Radiation Oncology Breast Site leader, and is Professor in the Departments of Radiation Oncology and Obstetrics and Gynecology at the University of Toronto. He did his MD degree and postgraduate training in Radiation Oncology at the University of Toronto and Royal Marsden Hospital. Dr. Fyles has research interests in translational and drug development clinical trials in gynecologic cancer, clinical studies of the tumour microenvironment, and clinical trials in breast cancer.

Meredith Giuliani, MD Med FRCPC

Meredith Giuliani is an assistant professor in the University of Toronto, Department of Radiation Oncology and a radiation oncologist in the Radiation Medicine Program at the Princess Margaret Cancer Centre. She received her MBBS qualification from the University of London, England and her Master’s of Education from the University of Toronto. She completed her residency training at the University of Toronto. She is the Chair of the Canadian Association of Radiation Oncology’s Education Committee and the Director of Undergraduate Education for the Department of Radiation Oncology at the University of Toronto, the Medical Director of Education for Princess Margaret Cancer Centre and the Cancer Care Ontario Smoking Cessation Champion for Toronto Central South. Her research interests include education technology development, outcomes research in lung cancer and curriculum development.

David Jaffray, PhD

David Jaffray graduated from the University of Alberta with a B.Sc. in Physics (Hons.) in 1988 and completed his Ph.D. in the Department of Medical Biophysics at the University of Western Ontario in 1994. Following graduation, he took a position as Staff Physicist in the Department of Radiation Oncology at William Beaumont Hospital in Michigan where he instigated a direction of research that garnered funding from the NIH and from congressionally-directed funding programs. Dr. Jaffray became a Board Certified Medical Physicist (ABMP – Radiation Oncology) in 1999. In 2002, Dr. Jaffray joined the Princess Margaret Hospital in Toronto as Head of Radiation Physics and a Senior Scientist within the Ontario Cancer Institute. David holds the Fidani Chair in Radiation Physics, is the Director of the TECHNA Institute for Health Technology Development at the University Health Network and recently became the Executive Vice President of Technology and Innovation at the University Health Network. He is a Professor in the Departments of Radiation Oncology, Medical Biophysics, and Institute for Biomaterials and Biomedical Engineering at the University of Toronto. His primary area of research has been in the development and application of image-guided therapy. He has over 5 patents issued and several licensed, including, kilovoltage cone-beam computed tomography for image-guided radiation therapy. Dr. Jaffray has >200 peer-reviewed publications in the field, >100 invited lectures, and holds numerous peer-review and industry sponsored research grants. He sits on numerous scientific and research boards and has contributed to the NIH and CIHR grant review process for several years. He is an active member of the AAPM and teaching role in workshops and annual meeting of the American Society of Therapeutic Radiation Oncology (ASTRO). He has an active interest in commercialization and led the development of a variety of commercial products including software and hardware for QA and the development of small animal irradiator systems for basic research. He has successfully supervised over 20 graduate students and fellows.

Otis Webb Brawley, MD MACP FASCO FACE

Otis Webb Brawley is an acknowledged global leader in the field of cancer prevention and control. As the chief medical and scientific officer and executive vice president of the American Cancer Society, he is responsible for promoting the goals of cancer prevention, early detection, and quality treatment through cancer research and education. He champions efforts to decrease smoking, improve diet, and provide the critical support cancer patients need. He also guides efforts to enhance and focus the Nation’s research program, upgrade the Society’s advocacy capacity, and concentrate community cancer control efforts in areas where they will be most effective. Dr. Brawley currently serves as professor of hematology, oncology, medicine and epidemiology at Emory University. He is also a medical consultant to the Cable News Network (CNN). From April of 2001 to November of 2007, he was director of the Georgia Cancer Center at Grady Memorial Hospital in Atlanta, and deputy director for cancer control at the Winship Cancer Institute at Emory University. He previously served as a member of the Society’s Prostate Cancer Committee, co-chaired the U.S. Surgeon General’s Task Force on Cancer Health Disparities, and filled a variety of positions at the National Cancer Institute (NCI), most recently serving as Assistant Director.

Dr. Brawley has served on a number of advisory committees including: the NIH Committee on Women’s Health; the Centers for Disease Control and Prevention Advisory Committee on Breast Cancer in Young Women; the Centers for Disease Control and Prevention Breast and Cervical Cancer Early Detection and Control Advisory Committee; and the Food and Drug Administration Oncologic Drug Advisory Committee. He chaired the NIH Consensus Panel on the Treatment of Sickle Cell Disease. He has been listed by Castle Connelly as one of America’s Top Doctors for Cancer. Among numerous other awards, he was a Georgia Cancer Coalition Scholar and received the Key to St. Bernard Parish for work in the U.S. Public Health Service in the aftermath of Hurricane Katrina. He is a fellow of the American Society of Clinical Oncology, a Fellow of the American College of Epidemiology and one of less than 1300 physicians to be named a Master of the American College of Physicians in its more than 100 year history. Dr. Brawley is also a member of the National Academy of Medicine.

Dr. Brawley graduated from the University of Chicago, Pritzker School of Medicine; trained in internal medicine at Case-Western Reserve University, and in medical oncology at the National Cancer Institute.

Sumit Gupta, MD PhD FRCPC

Sumit Gupta is a Staff Oncologist and Clinician Investigator at the Hospital for Sick Children, an Assistant Professor at both the Faculty of Medicine and the Institute for Health Policy, Management and Evaluation at the University of Toronto, and an Adjunct Scientist with the Cancer Research Program at the Institute for Clinical Evaluative Sciences. He completed a PhD in Clinical Epidemiology from the University of Toronto, during which time he was supported by a CIHR Fellowship Award. He is currently one of the chairs of an ongoing Lancet Oncology Commission on Sustainable Pediatric Cancer Care in low and middle income countries. Sumit has worked extensively with pediatric oncologists and policymakers throughout Latin America, the Caribbean, and India. He currently holds grant funding from The Garron Family Cancer Centre, Alex’s Lemonade Stand, CIHR and the Canadian Cancer Society Research Institute.

Edward L. Trimble, MD MPH

In 2011 Dr. Harold Varmus, then Director of the US National Cancer Institute (NCI) appointed Dr. Trimble the founding Director of NCI’s new Center for Global Health (CGH). Under Dr. Trimble’s leadership CGH has become the coordinating point for NCI’s work to strengthen global cancer research, to train future generations of global cancer researchers, and to help translate research into policy for cancer control. NCI CGH has been recognized worldwide for its work in the development of affordable cancer technology, national cancer control planning, and training.

From 1991 to 2011 Dr. Trimble worked in NCI’s Division of Cancer Treatment and Diagnosis, with responsibility for national and international NCI-sponsored treatment trials in gynecologic cancer, as well as cancer trials for the elderly, adolescents and young adults, international collaboration in cancer clinical trials, and strengthening assessment of patient-reported outcomes and health-related quality of life in cancer trials. He spearheaded the NCI’s Clinical Announcements regarding chemoradiation for cervical cancer (1999) and intraperitoneal chemotherapy for ovarian cancer (2006), both of which changed the standard of care for women with gynecologic cancer. For his work at the US NCI Dr. Trimble has received two Public Health Service Commendation Medals, six NIH Merit Awards, and the NCI Director’s Gold Star Award.

Dr. Trimble graduated from Harvard University (BA), the Johns Hopkins University School of Medicine (MD), and the Johns Hopkins University Bloomberg School of Public Health (MPH). He trained in obstetrics/gynecology at Vanderbilt University Medical Center and in gynecologic oncology at Memorial Sloan-Kettering Cancer Center. He is board-certified in obstetrics and gynecology, as well as in gynecologic oncology, by the American Board of Obstetrics and Gynecology.

Sir George Alleyne

Sir George Alleyne, a native of Barbados, became Director of the Pan American Health Organization (PAHO), Regional Office of the World Health Organization (WHO) on 1 February 1995 and completed a second four-year term on 31 January 2003. In 2003 he was elected Director Emeritus of the PASB. From February 2003 until December 2010 he was the UN Secretary General’s Special Envoy for HIV/AIDS in the Caribbean. In October 2003 he was appointed Chancellor of the University of the West Indies. He currently holds an Adjunct professorship on the Bloomberg School of Public Health, Johns Hopkins University.

Dr. Alleyne has received numerous awards in recognition of his work, including prestigious decorations and national honors from many countries of the Americas. In 1990, he was made Knight Bachelor by Her Majesty Queen Elizabeth II for his services to Medicine. In 2001, he was awarded the Order of the Caribbean Community, the highest honor that can be conferred on a Caribbean national.

Sanchia Aranda, RN PhD

Professor Sanchia Aranda was appointed as CEO of Cancer Council
Australia in August 2015. In this role Sanchia leads cancer policy and advocacy development, ensuring a strong evidence base is used to inform cancer control in Australia. She also holds academic appointments with the School of Health Sciences, University of Melbourne and the Faculty of Nursing, University of Sydney and is a research fellow at the Peter MacCallum Cancer Centre. She has 38 years’ experience in cancer control and has held roles in healthcare, research, tertiary education and government prior to joining the not-for-profit sector. She has held significant leadership roles in Australian Cancer Control, including 8 years on the Advisory Council for Cancer Australia (2006-2015).

Sanchia also has extensive international cancer control experience, with 16 years on the board of the International Society of Nurses in Cancer Care, including 4 as President (2006-2010). She is the President for the Union for International Cancer Control and has been on the board of UICC for 6 years. She is also a board member for the International Collaboration on Cancer Reporting. Her contributions to cancer control have been recognized nationally and internationally through awards and keynote speaker invitations. In 2013 she was named the 4th Peter MacCallum Cancer Centre Distinguished Fellow for her contributions to Cancer Nursing and in 2016 received the International Society of Nurses in Cancer Care Distinguished Merit award.

Rifat Atun

Rifat Atun is Professor of Global Health Systems at Harvard University and Director of the Health Systems Cluster. He is the Faculty Chair for the Harvard Ministerial Leadership Initiative. In 2006-2014 he was Professor of International Health Management at Imperial College London.

In 2008-12 Professor Atun served as a member of the Executive Management Team of the Global Fund to Fight AIDS, Tuberculosis and Malaria in Switzerland as the Director of the Strategy, Performance and Evaluation.

Professor Atun’s research focuses on global health systems, global health financing, and innovation in health systems. He has worked extensively with governments, the UK DFID, the World Bank, World Health Organization, and other international agencies to design, implement and evaluate health system reforms.

Dr. Atun studied medicine at University of London as a Commonwealth Scholar and undertook his postgraduate medical studies and MBA at University of London and Imperial College London. He is a Fellow of the Faculty of Public Health of the Royal College of Physicians (UK), a Fellow of the Royal College of General Practitioners (UK), and a Fellow of the Royal College of Physicians (UK).

Mary Hooey, CMP

Mary Hooey has been employed at the Princess Margaret Cancer Centre since 1997 and is currently the Business Administration Manager. She supports educational program initiatives and activities for the Cancer Education Program. Mary has more than 20 years’ experience in event planning and sits on various committees for local, national and international conference planning committees. In 2016, she received the Excellence in Education Support Award. In her spare time, she enjoys volunteering for fundraising activities, bike riding and has rode in the Ride to Conquer Cancer for 7 years!

Amit Oza MBBS, MD, FRCPC

Amit Oza MBBS, MD, FRCPC is Head of the Department of Medical Oncology & Hematology, and Medical Director of the Cancer Clinical Research Unit at Princess Margaret Cancer Centre (PM). He is also co-Director of the Drug Development Program at PM, Scientist at the Ontario Cancer Institute, and Professor of Medicine at University of Toronto. Dr. Oza has been PI and co-investigator in >100 phase I, II and III trials for gynecological cancer and advanced colorectal malignancies. Under his direction, the gynecology group is one of the largest ovarian cancer (OC) clinical trials groups consistently accruing >30% of all patients seen onto clinical trials (>120/yr) at PM. Since 2011, he has obtained >$26.9M in peer-reviewed funding and has published >180 articles (all types) including the New England Journal of Medicine (IF=53); Lancet Oncology (IF=16), and Journal of Clinical Oncology (IF=16.4).

Miriam Schneidman

Miriam Schneidman is a Lead Health Specialist in the Africa Region of the World Bank. She has more than 35 years of experience working on health and human development issues in the Africa and Latin America and Caribbean Regions of the World Bank.

Schneidman has led the design and development of investment operations in Africa (e.g. Burundi, Burkina Faso, Cameroon, Democratic Republic of Congo, Kenya, Rwanda, Nigeria, Tanzania, and Uganda) and Latin America and the Caribbean (e.g. Bolivia, Colombia, Haiti). She was extensively involved in the World Bank’s Multi-Country HIV/AIDS Program for Africa (MAP), leading the roll-out of AIDS treatment programs, brokering partnerships, and managing several operations, including the Burkina and Rwanda MAPs. Over the past few years she has led a unique regional project in East Africa to strengthen diagnostic and surveillance systems. Most recently, she organized a South-South Knowledge Exchange to support countries in East and Southern Africa to share lessons and experiences in cancer care and control. In the past she worked extensively on family planning, reproductive health, and demographic issues.

Schneidman has written on the subject of vulnerable youth (Targeting At-Risk Youth, 1996), demographic issues (Mortality and Fertility Trends in Zaire, 1990), co-authored books and articles on women’s health (Women’s Health in Latin America and the Caribbean, 2001), performance based financing (Performance Incentives for Global Health, 2009), and laboratory systems (Laboratory Professionals in Africa: The Backbone of Quality Diagnostics, 2014) and cancer care and control (Cancer Care and Control South-South Knowledge Exchange, 2015).

Schneidman currently represents the World Bank on the Stop TB Partnership Coordinating Board. In the past she served as a member of the Center for Global Development Performance-Based Incentives Working Group and the Harvard Global Task Force on Expanded Access to Cancer Care and Control. Schneidman holds degrees in Economics from the University of Maryland and in Public Health from The Johns Hopkins University. She is fluent in French, Spanish and Romanian.

Dr David Collingridge

Dr David Collingridge has been Editor-in-Chief of The Lancet Oncology since March 2002, and is also the Publishing Director for The Lancet’s Specialty Journals. Prior to his appointments at The Lancet, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK. Dr Collingridge has published numerous peer-review articles, editorials, opinion pieces, and news reports, and has co-authored a text book on radiobiology. He currently also holds the position of Clinical Associate Professor of Radiation Medicine at Hofstra/Northwell Health, Lake Success, NY, USA.

Rengaswamy Sankaranarayanan, MD

Rengaswamy Sankaranarayanan was trained as radiation and clinical oncologist in the University of Kerala, India and had post-doctoral training at the Pittsburgh Cancer Institute, USA and the MRC Biostatistics Unit, Cambridge, UK. After working in primary care, clinical oncology and cancer control in India for about 11 years, Dr. Sankaranarayanan joined the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO) in 1993, where he was the Head of the Early Detection and Prevention Section until 2014 and is currently the Special Advisor on Cancer Control and Head of the Screening Group. He is committed to research, training, program development and technical assistance in early detection and cancer control, particularly in low- and middle income countries (LMICs). He has conceived, conducted and coordinated multinational studies in Asia, Africa and Latin America addressing feasible, affordable and effective methods of early detection and control of cervix, breast, colorectal and oral cancers and has also addressed survival outcomes from major cancers in LMICs. He has provided technical support to national cancer control programs and national screening programs in several LMICs. Dr Sankaranarayanan has taught in over 70 international courses on cancer early detection and control. He is an author in more than 260 papers in international peer-reviewed journals.

Anthony Miceli

Anthony Miceli is a strategic advancement professional with 20 years of experience in creating revenue growth in the not for profit sector. Currently holds the position of Executive Director, Corporate and Foundation Relations at the University of Toronto. Previous to U of T, Anthony was the Vice President of Development for the Canadian Breast Cancer Foundation and the VP, Business Development and Marketing, Special Olympics Canada. Throughout his career, Anthony’s primary focus has been to lead the corporate development efforts for a variety of charitable organizations.

In 2004, after identifying a tremendous need within the non-profit market, Anthony created jla consulting, an agency that exclusively focused on supporting the strategic fund development and marketing needs of small to mid-sized charities across the country. Anthony has had the privilege and opportunity to provide leadership for a diverse range of organizations including; international development agencies, national membership organizations, and a vast array of local community groups.

In his current role, Anthony works with colleagues across all three campuses to actively manage the university’s sponsorship and philanthropic interests amongst U of T’s institutional partners.

Gary Rodin, MD, FRCPC

Gary Rodin is the Joint University of Toronto/University Health Network Harold and Shirley Lederman Chair in Psychosocial Oncology and Palliative Care and is Head of the Department of Supportive Care at the Princess Margaret Cancer Centre in Toronto.

Dr. Rodin is the Director of the Global Institute of Psychosocial, Palliative and End-of-Life Care (GIPPEC) and a Professor of Psychiatry at the University of Toronto. He is a clinician-investigator who has published widely on the psychiatric and psychosocial aspects of cancer and other medical illnesses. Under his leadership, the Department of Supportive Care at the Princess Margaret has now achieved an international reputation for its academic and clinical excellence.

Dr. Rodin has authored texts on Depression in the Medically Ill, and on the Psychiatric Aspects of Transplantation and is currently leading research on the psychological impact of advanced and terminal disease in affected patients and their families.

Hellen Gelband

Hellen Gelband is an independent global health policy consultant, working currently with the University of Toronto and the University of Oxford. She was most recently Associate Director for Policy at the Center for Disease Dynamics, Economics & Policy (CDDEP). Her work spans infectious disease, particularly malaria and antibiotic resistance, and non-communicable disease policy, mainly in low- and middle-income countries. Before joining CDDEP, she conducted policy studies at the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the U.S. National Academies, and a number of international organizations. She is an editor in the Cochrane Infectious Diseases Group and an editor of Disease Control Priorities, 3rd edition. At CDDEP, she led the Global Antibiotic Resistance Partnership (GARP) since its inception in 2008.

Eduardo L. Franco, MPH, DrPH, FRSC, FCAHS, OC

He is James McGill Professor and Chairman, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal. Since 1985, he has conducted epidemiologic research on the causes of cancer and on the means to prevent it or to improve patient survival, topics on which he has published more than 440 articles, 60 book chapters, and two books. He is mostly known for his contributions to our understanding of human papillomavirus infection as the cause of cervical cancer and using this knowledge to prevent this cancer via vaccination and improved screening strategies. For his work on these topics, he received Lifetime Achievement Awards from the American Society for Colposcopy and Cervical Pathology (2010) and from the International Papillomavirus Society (2015), the Women in Government’s (US) Leadership Award (2008), the Canadian Cancer Society’s Warwick Prize (2004), and the McLaughlin-Gallie Award from the Royal College of Physicians and Surgeons of Canada (2011). He mentored than 100 graduate students and post-doctoral fellows. He is the Editor-in-Chief of Preventive Medicine and has served in the editorial boards of several top-tier journals in oncology and epidemiology. He is Officer of the Order of Canada (2016) and Fellow of the Royal Society of Canada (2011) and of the Canadian Academy of Health Sciences (2012).

Ophira Ginsburg, MSc MD FRCPC

Dr. Ginsburg is medical oncologist with expertise in cancer genetics, epidemiology, prevention, and screening. Her research spans more than a decade in global cancer control and women’s health equity. Since 2004, she has developed a program of population intervention research and training in global cancer control, with projects in Vietnam, Bangladesh, and Tanzania. She is principal investigator on studies of population differences in breast cancer risk factors; and of public health interventions to improve access to cancer services for women in low-income countries, and women from ethno-cultural minority communities in North America.

She is an Advisor to the National Cancer Hospital and National Institute for Cancer Control of Vietnam, and is a faculty member of the Institute of Cancer Policy, King's College London and the James P Grant School of Public Health at BRAC University, Bangladesh. She serves on several NGO advisory boards including Young Professionals Chronic Disease Network (U.S.), Global Focus on Cancer (U.S.), and is a founding member of WEMA, Women's Health Equity Through Mobile Approaches (Canada).

From October 2015- November 2016, Dr Ginsburg worked in Geneva Switzerland, as the Cancer Management Lead for the World Health Organization. In March 2017 she began a new post as Director of the High Risk Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, and Associate Professor in the Department of Population Health, NYU School of Medicine.

Dr. Ginsburg has authored 58 peer-reviewed articles, including a three-part commissioned series for The Lancet, “Health, equity, and women’s cancers”. A global effort with 40+ authors from 18 countries, the Series was published along with invited commentaries at the World Cancer Congress (Paris, Nov 2, 2016). She is a founding editorial board member of the Journal of Global Oncology (ASCO) and Journal of Cancer Policy (Elsevier).

May Abdel-Wahab

Dr May Abdel-Wahab is the Director of the Division of Human Health at the International Atomic Energy Agency, Vienna Austria. She has over 30 years of patient care, teaching and research experience in radiation oncology. Before joining IAEA she was section head of GI Radiation Oncology at the Cleveland Clinic, USA and Professor at the Cleveland Clinic Lerner School of Medicine, Case Western University. Her research focused on evaluating radiation therapy for prostate and GI cancers as well as quality assurance and access in radiotherapy. She served on various National and International committees, such as the UN inter-agency Task Force (UNIATF) on Non-Communicable Diseases (NCDs), as Chair of the ASTRO Committee for Healthcare Access & Training, as Co-Chair IHE-RO planning committee and on the UN Joint Programme on Cervical Cancer Control Steering committee, among others. She has published over 150 scientific publications, including scientific papers , abstracts and book chapters and has served on several advisory boards and professional journal editorial boards. As scientific secretary , she organized numerous national symposia and scientific meetings. She was honoured as a fellow of the American board of Radiology, American Society of Radiation Oncology and was on the Best doctors in America listing. She has also served on expert panels such as the ACR appropriateness criteria panels in prostate cancer and gastrointestinal cancers. Her interests related to global health are in cancer control, healthcare access and training, as well as novel solutions to disparity and diversity issues in radiation oncology.

Anil D'Cruz

Anil K D’cruz is Director at the Tata Memorial Hospital, Mumbai, India and Professor and Surgeon in the Department of Head and Neck Surgery. He graduated from St.John’s Medical College, Bangalore in 1984 & went on to complete his Masters in general surgery at the Mumbai University. He is also a Diplomate of the National Board, New Delhi. In recognition of his professional standing in the field of Surgery, he was awarded the Honorary FRCS from the Royal College of Surgeons, London.

Dr. D’Cruz has over 30 years experience in the field of Surgical Oncology focussing primarily on head and neck cancers. His major areas of interest are management of neck metastasis, conservative laryngeal surgery, cancers of the oral cavity, thyroid, quality of life issues and global health. He is actively involved in research and plays a pivotal role in a number of trials. As principal investigator, he has successfully published results of a prospective randomized controlled trial evaluating the role of elective neck dissection in the management of early oral cancers that is practice defining. In addition, he has been principal investigator of a Phase I trial evaluating the role of Interstitial Photodynamic Therapy (PDT) in advanced cancers and was the Global Principal Investigator for a trial evaluating the role of PDT in recurrent, refractory head and neck tumors. He is also the principal investigator of multicentric, multinational trials studying the role of targeted therapy in head and neck cancers in the concurrent, adjuvant and the palliative setting. He has been involved in research on the use of curcumin, proteomics, gene therapy in head and neck cancer.

Dr. D’Cruz has leadership position in a number of cancer organizations. He is on the Board of Directors on the Union International on Cancer Control, Geneva as well as Governing Council, Foundation of Head and Neck Oncology, India. He is also on the Governing Board/Scientific Advisory Board of various leading institutions such as Gulf Medical University, All India Institute of Medical Sciences, Rishikesh, National Institute of Biomedical Genomics, Kalyani amongst others. He has been past-president of the Asian Society of Head and Neck Oncology, Foundation of Head and Neck Oncology, India; Task force, Department of Biotechnology, Government of India, and Cancer guidelines, Indian Council of Medical Research.

Dr D’cruz is a member of numerous professional bodies in the country which include, The Indian Society of Surgical Oncology, Association of Surgeons of India, Indian Society for Cancer Research, Indian Association of Surgical Oncology, Foundation of Head and Neck Oncology, Indian Society of Head and Neck Oncology and the Action council for Tobacco Control.

Dr D’Cruz has over 200 peer reviewed publications, and chapters to his name. He is an editor of a two-volume book on Head and neck surgery and also the to-be-released Manual of Clinical Oncology and Hamilton Bailey Clinical Signs. He has delivered over 300 invited lectures and orations and has been visiting professor to several institutions, both nationally and internationally. He is a member of the Editorial Board of Head Neck journals and also is a reviewer for several scientific journals both national and international.

Felicia Marie Knaul

Felicia Marie Knaul is the Director of the University of Miami Institute for Advanced Study of the Americas, Professor at UM’s Miller School of Medicine, and Full Member of the Cancer Control Program at Sylvester Comprehensive Cancer Center. She maintains a strong program of research and advocacy in Latin America, especially in Mexico, where she is the Senior Economist at the Mexican Health Foundation and Founding President of Tómatelo a Pecho, A.C. Dr. Knaul is also the President (2016-18) of the Latin American Union against Women’s Cancers (ULACCAM). In 2017, she was inducted into the National Academy of Medicine of Mexico and awarded Level III of the Mexican National System of Researchers.

As a result of her breast cancer experience, in 2008 Dr. Knaul founded Tómatelo a Pecho, a Mexico-based non-profit agency that promotes research, advocacy, awareness, and early detection in Latin America. She has lectured globally on the challenge of breast cancer in low and middle-income countries, both as patient-advocate and health systems researcher. She recounts her personal experience in Tómatelo a Pecho (Grupo Santillana, 2009) and Beauty without the Breast (Harvard University Press/ Harvard Global Equity Initiative, 2013). Her story and her work have been featured in Reforma, The Miami Herald, The Lancet, Science, WHO Bulletin, Newsweek en Español, and Cancer Today.

Dr. Knaul has designed, created and coordinated several research networks. From 2014-2017 she served as Chair of the Lancet Commission on Global Access to Palliative Care and Pain Relief, lead authoring the Commission’s October 2017 final report, “Alleviating the access abyss in palliative care and pain relief – an imperative of universal health coverage.” As Director of the Harvard Global Equity Initiative, she founded and directed the Global Task Force on Expanded Access to Cancer Care and Control, serving as lead author and co-editor of the task force’s publication Closing the Cancer Divide: An Equity Imperative (Harvard University Press/ Harvard Global Equity Initiative, 2012), and was a member of the Global Task Force on Radiotherapy for Cancer Control (GTFRCC), taking a leadership role in the global reports that were produced. From 2012-2015, she was a member of the Lancet Commission on Women and Health and a leading co-author of its June 2015 report. Her areas of research are focused on global health and include cancer and especially breast cancer in low- and middle-income countries, women and health, health system strengthening and reform, health financing, and access to pain control and palliative care.

Dr. Knaul has produced more than 190 academic and policy publications, authored and lead-edited academic books, and serves on the advisory board or editorial board of several medical and health care publishers, including The Lancet Global Health and the Journal of Global Oncology, among others. She has also served on numerous boards, including the Union for International Cancer Control (2010-2014). Dr. Knaul received M.A. and Ph.D. degrees in economics from Harvard University and a B.A. in international development from the University of Toronto.

She and her husband, Dr. Julio Frenk, have two children, Hannah Sofia (21 and studying chemistry) and Mariana Havivah (13). Her mother Marie and brother Jonathan live in Canada.

Ryan Lindsay

Ryan Lindsay is the Senior Development Officer at the Dalla Lana School of Public Health, University of Toronto, where he works with faculty and alumni to secure funding for research, student scholarships and advance the mission of the School.

Ryan received his BA Honours Sociology with Business Administration in 2000 from Wilfred Laurier University. He completed teachers’ college in New Zealand, has a certificate in Strategic Communications from University of Toronto, and is currently pursuing his Masters of Education at University of Toronto.

In his spare time Ryan plays squash, Ultimate Frisbee and he runs a couple of not-for-profits that support Waldorf education in Canada and Central America.

Cindy Gauvreau

Cindy Gauvreau is a health economist at the Canadian Partnership Against Cancer, where she uses the OncoSim microsimulation model to study population level impacts of Canadian cancer control strategies. While a post-doctoral fellow and economist with the Centre for Global Health Research at St. Michael’s Hospital in Toronto, she coordinated publication of the Disease Control Priorities Network book "DCP3:

Cancer", a volume authored by international groups of cancer researchers and aimed at cancer control policy-making in low- and middle-income countries. Her research interests include cost-effectiveness analysis of cancer screening strategies, tobacco control and infectious disease control, in both Canada and low- and middle-income countries.

Cindy has a PhD in Health Services Research from the Institute of Health Policy, Management and Evaluation and an MA in Economics from the University of Toronto.

Anna Dare MBChB PhD

Anna Dare MBChB PhD is a general surgery resident at the University of Toronto and a post-doctoral fellow at the Centre for Global Health Research, St Michael’s Hospital. Her major interest is expanding access to surgical care in low- and middle-income countries (LMICs) in order to meet emerging health challenges. Her research examines the relationships between surgical access, coverage and outcomes using large-scale epidemiological studies and geostatistical methods. Originally from New Zealand, Anna received her medical degree from the University of Auckland. She then completed her PhD at the University of Cambridge, England as a Commonwealth Scholar. Anna has served as a Commissioner on the Lancet Commission on Global Surgery and the Lancet Oncology Commission on Global Cancer Surgery, and is an author for the Disease Control Priorities Project (3rd edition) Cancer Volume. Her work has taken her throughout the Western Pacific, South Asia, West Africa and most recently to Canada.

Prof. Franco Cavalli, M.D.

Franco Cavalli, born in 1942, was the Scientific Director of the Oncology Institute of Southern Switzerland (IOSI) in Bellinzona (Switzerland) until 2017. He created this institute, which encompasses medical oncology, radio-oncology, nuclear medicine, palliative care, hematology and an important research division. He is currently still President of the Foundation, which manages the Institute of Oncology Research (IOR), located in Bellinzona (Switzerland). He is Professor (Titularprofessor) of medical oncology at the Medical Faculty in Bern (Switzerland). He has an international reputation for the treatment of and research into malignant lymphoma and new drugs. Every second year he organizes in Lugano the International Conference on Malignant Lymphoma, which is the most important congress on this topic worldwide. He has been very active also in the field of the clinical evaluation of new cancer drugs. The quality of his work has been recognized by the award of 24 national and international prices, including the Petzcoller Award for special dedication to oncology and the ESMO Lifetime Achievement Award. He has published more than 600 articles in peer-reviewed journals and has contributed to many books on cancer, including the Textbook of Medical Oncology, which he edited together with S. Kaye (London), H.H. Hansen (Copenhagen) and D. Armitage (Omaha, Nebraska).

He was Founding Editor and Editor-in-Chief of Annals of Oncology, Europe’s premier medical oncology journal, from 1990 to 2000, and he is on the Editorial Board of several other journals. In 1996, he founded the International Extranodal Lymphoma Study Group (IELSG, www.ielsg.org), which encompasses now more than 200 institutions in 4 continents. IELSG is the leading cooperative group in the field of the biological and clinical studies in the field of extranodal lymphomas.

Franco Cavalli has been President of the Swiss Cancer League and is Chairman of the Scientific Committee of the European School of Oncology (ESO) and of the World Oncology Forum (WOF). He was President of the International Union Against Cancer (UICC) between 2006 and 2008. He has been member of WHO committee of selection of essential medicines for cancers since 2015. He was member of the Swiss Parliament between 1995 and 2007.

CS Pramesh

Pramesh is the Professor and Head of Thoracic Surgery at the Tata Memorial Centre, Mumbai. He is the convener for the National Cancer Grid, a large network of over 120 cancer centres in India. The mandate of the National Cancer Grid is primarily to provide uniform standards of cancer care across the country. Pramesh is highly committed to efforts towards reducing inequities in cancer care and making cancer treatment accessible to all geographic regions and strata of society. He is also a visiting professor at the Division of Cancer Studies, King’s College London and the Institute of Cancer Policy, King’s Health Partners, London.

His primary clinical areas of interest include treatment of esophageal and lung cancers and minimally invasive surgery. He is the Secretary of the Indian Society for Diseases of the Esophagus and Stomach (ISES). He is the Principal Investigator in several investigator-initiated research studies including randomized trials on cancer screening, surgical techniques, and neoadjuvant treatment of thoracic cancers. He has written more than 170 peer-reviewed journal articles, abstracts and book chapters on various topics including thoracic oncology, clinical research methods, translational research and cancer policy.

Pramesh has strong interests in clinical trial designs, surgical trials, comparative effectiveness research, promoting collaborative research and cancer policy. He successfully completed the Post Graduate Diploma in Clinical Trials offered by the London School of Hygiene and Tropical Medicine, University of London in 2010. He is keen on promoting training in clinical research methods and conducts several courses on clinical research methodology, biostatistics and scientific writing. He serves on the core committee of the Clinical Research Secretariat of the hospital.

Benjamin Olney Anderson, M.D., F.A.C.S.

Fred Hutchinson Cancer Research Center

Chair and Director
The Breast Health Global Initiative

Joint Full Member, Epidemiology
Division of Public Health Sciences

University of Washington School of Medicine

Professor of Surgery
Department of Surgery

Professor of Global Health - Medicine
Department of Global Health

Director, Breast Health Clinic
Seattle Cancer Care Alliance

As director of the Breast Health Clinic at the Seattle Cancer Care Alliance (SCCA), Dr. Anderson is Professor of Surgery and Global Health Medicine at the University of Washington (UW). Dr. Anderson’s clinical practice is devoted to the care of patients with breast health issues and breast cancer. Since 2005 he has published on novel surgical techniques in oncoplastic breast surgery, procedures that simultaneously improve oncologic and cosmetic outcomes in breast conservation surgery. Dr. Anderson is past-president of the American Society of Breast Disease (ASBD) and currently serves as vice chair of the National Comprehensive Cancer Network (NCCN) Breast Panel and chair of the NCCN International Program Committee.

Dr. Anderson’s is an internationally recognized leader in global cancer control. With joint appointments at the Fred Hutchinson Cancer Research Center Division of Public Health Sciences and the UW Department of Global Health, Dr. Anderson created in 2002 and chairs the Breast Health Global Initiative (BHGI), a unique program to develop “resource-stratified” guidelines for breast cancer early detection, diagnosis, treatment and palliative care in low- and middle-income countries (LMICs). In 2011 the American Society of Clinical Oncology (ASCO) awarded Dr. Anderson their Partners in Progress Award and in 2013 the National Consortium of Breast Centers (NCBC) awarded him their 2013 Inspiration Award, recognizing his dedicated efforts to improve the quality and effectiveness of breast cancer care around the globe. Since 2012, Dr. Anderson has served on the Board of Directors of the Union for International Cancer Control (UICC). Dr. Anderson now co-chairs the Breast Cancer Initiative 2.5 (BCI2.5), a global campaign to reduce disparities in breast cancer outcomes for 2.5 million women in the next decade.

Yolande Lievens - MD, PhD

is the chair of the radiation oncology department of the Ghent University Hospital, Belgium, and associate professor at the Ghent University.

Her clinical focus lies on radiation therapy for thoracic malignancies, with a special attention for the role of radiotherapy in hematology and in breast cancer. Apart from the clinics, she has always been closely involved in the organizational aspects of radiotherapy, in the position of radiotherapy within multidisciplinary oncology and in the financial and health economic aspects of cancer care. This interest in health services research is substantiated in her collaboration in the ESTRO-HERO (Health Economics in Radiation Oncology) project and in the Global Task Force on Radiotherapy for Cancer Control, that is now continued in the ESTRO-GIRO (Global Impact of Radiotherapy in Oncology) project. Last but not least, she has a vested interest for quality issues in radiation oncology, not only in terms of quality assurance but also regarding the impact of radiation treatments on quality of life.

To achieve these goals, she is a strong advocate of collaboration; interdisciplinary among radiotherapy professionals and multidisciplinary with the other oncology care givers. In addition, as the current president of ESTRO, she strongly promotes partnership with the other stakeholders, the national radiotherapy societies, the patients, the industry partners and the policy makers.

In view of providing state-of-the-art radiotherapy to all cancer patients who need it, she is convinced that evidence - clinical as well as economical - is key to sustain innovation in and improve access to radiotherapy within the nowadays often-limited health care budget.

Dr. Faith Mwangi-Powell - Global Director, The Girl Generation

Dr. Faith Mwangi-Powell, MSc, Ph.D. is a public health expert with extensive experience in managing complex public health programmes across Africa. Faith’s experience includes serves as the Global Director for The Girl Generation a DFID funded, ten country social change communication initiative to end Female Genital Mutilation (FGM), where she provides thought leadership, strategic direction, and global partnership development, resource leveraging and technical oversight for all activities globally. Previously, Faith worked as the founding Executive Director of the African Palliative Care Association and supporting palliative care global advocacy, partnership development and services development in over 20 African countries. Faith has also worked as the University Research Company’s Chief of Party for the USAID- funded ASSIST Programme in Kenya where she provided technical leadership and managerial oversight for the design and implementation of project quality improvement strategy in HIV Care and Treatment, nutrition, maternal new born and child Health (MNCH), and malaria. Before that Faith worked in palliative care global advocacy and financing with the Public Health Program of the Open Society Foundations, based in New York and providing strategic leadership around palliative care advocacy, accountability and resource leveraging. Faith is a passionate and results-orientated leader coming from a community health background and with an established background and specialist knowledge in palliative care, HIV/AIDS including OVC and child protection, advocacy, sexual reproductive health, human rights, gender, and social change communication.

Academically, Faith holds a Master’s degree in Population Policies and Programmes from Cardiff University, Wales, and a PhD in 'Women’s economic development and fertility behavior' from the University of Exeter, England. She has published in internationally renowned peer-reviewed scientific journals with a major focus on sexual and reproductive health, community health, and palliative care, primarily in resource-limited settings.

Prof. Dr. M. Tezer Kutluk, MD, PhD, FAAP

Graduated from Hacettepe University Medical School Ankara-Turkey in third rank among graduates in 1981. Postdoctoral fellow and Fulbright scholar at MD Anderson Cancer Center USA (1992-94). Member of SIOP, ASCO, AACR, honorary member AAP, International Children’s Center, UNICEF National Committee. He had served as a leading healthcare executive at Hacettepe University; Vice-Director of Children’s Hospital (1997-1998), the Director of Oncology Hospital (1999-2007), Director of Children’s Hospital (2000-2007) and President of Institute of Child Health (2000-2004), President of Institute of Oncology (2004-2008), Board Member of Institute for Health Sciences (2000-2007), Member of Senate (2000-2011) & CEO of Hacettepe University Hospitals (2008-2011). ??He has 184 publications in peer reviewed international scientific journals and more than 1600 citation in international medical Journals and numerous abstracts in international meetings.

In addition to his experience on Research, Patient Care & Education in Pediatric Oncology, He has an extraordinary experience on global oncology matters through his involvement in global oncology matters through major oncology societies. He has a long term experience on NGO management; “UICC-International Union for Cancer Control - Board Member – Geneva - Switzerland (2008 - 2012)” “President of Turkish Association for Cancer Research and Control, Ankara-Turkey (2004-2012)”, “President of European Cancer Leagues-ECL – Brussels-Belgium (2009-2011)”, “President of Turkish National Pediatric Society (2009-2012)”, “President of Turkish Pediatric Oncology Group (2011-2013)”. Chair of Turkish UNICEF national committee (2014-2016) His experience on healthcare management during the last 15 years brought him to the top of the Hacettepe University Hospitals as CEO between 2008-2011. He is named as honorary fellow of by American Academy of Pediatrics (FAAP) in May 2014. He is Associate Editor of the Journal of Global Oncology published by ASCO. He was the President of “UICC, Union for International Cancer Control, Geneva-Switzerland” for the term of 2014-2016. He recently elected to the NCDAlliance Board Member in May 2017 (Geneva-Switzerland).

Jamal Khader

Jamal Khader is currently a Cons. Radiation Oncologist who specializes in Head and Neck, Genitourinary, Gastrointestinal and Lung Cancers at the King Hussein Cancer Center in Amman Jordan. He is the immediate Past President of the Jordan Oncology Society, and is an Ex Member of the UICC Board of Directors.

PATRICK J. LOEHRER, SR., M.D.

DISTINGUISHED PROFESSOR
DIRECTOR, IU MELVIN AND BREN SIMON CANCER CENTER
HH GREGG PROFESSOR OF ONCOLOGY
ASSOCIATE DEAN FOR CANCER RESEARCH,
INDIANA UNIVERSITY SCHOOL OF MEDICINE

PATRICK J. LOEHRER, SR., M.D. is a prolific clinical researcher and specialist in the treatment of a variety of cancers including testis, bladder, colon, pancreas and, most notably, thymus. His research on the drug, ifosfamide, led to its approval by the FDA. His research related to thymic cancer has been recognized with the Exceptional Service Award of the Foundation for Thymic Research. He has published over 68 papers and book chapters on thymic neoplasms and he was the clinical co-chair for the TCGA evaluating thymic cancer.

Dr. Loehrer was the founding chair of the Hoosier Oncology Group (now Hoosier Cancer Research Network) for two decades, which conducted trials in 20 countries around the world. Dr. Loehrer has served on the boards of the ECOG Foundation, the American Society of Clinical Oncology, and the American Board of Internal Medicine. Since 2009, Dr. Loehrer has been director of the IU Simon Cancer Center, a National Cancer Institute cancer center. He has numerous other awards including the Flick Family Fund Award, American Cancer Society Fellowship and the American Cancer Society Junior Faculty Award, the Glenn Irwin Experience Excellence Award, the ECOG Young Investigator Award, the Danielson Award, the Collaborator of the Year Award from the Walther Cancer Institute and the W. George Pinell Award. From the American Society of Clinical Oncology, Dr. Loehrer received the Special Recognition Award, and in 2017, was awarded the Allen S. Lichter Visionary Leadership Award.

Clifford Hudis

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the CEO of its Conquer Cancer Foundation and as Chairman of the Board of Governors of ASCO’s CancerLinQ. He previously served in a variety of roles at ASCO including as President during its 50th anniversary year, 2013-14. Before moving fulltime to ASCO he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, where he was also Professor of Medicine at the Weill Medical College of Cornell University. In this role he developed more effective treatments for all stages of breast cancer while also exploring novel prevention opportunities. His earliest work focused on translating the kinetic predictions of the Norton-Simon model into more effective dose-dense adjuvant chemotherapy programs. Then he and his team focused on the interplay of inflammation, obesity, and cancer finding low grade, chronic white adipose inflammation in most overweight and obese women. At ASCO his key initiatives include the acceleration of CancerLinQ, the society’s focused effort to increase insights and learning from the rapidly accumulating electronic records of routine care provided by clinicians.

Tim Evans

Senior Director of Health, Nutrition and Population at the World Bank Group. Prior to this he was the Dean of the James P Grant School of Public Health at BRAC University in Dhaka, Bangladesh (2010-13), and Assistant Director General at the WHO (2003-10). Dr Evans has been at the forefront of advancing global health equity and strengthening health systems delivery for > 20 years. While at WHO, he led the Commission on Social Determinants of Health. He co-founded the Global Alliance on Vaccines and Immunization (GAVI) and is a board member of a number of international health alliances.

Patricia Garcia

A global leader in drug and vaccine development, women’s health and health systems strengthening. She was the Minister of Health of Peru from 2016-2017. Prior to this, she served as the Dean of the School of Public Health and Administration at Peru’s Universidad Peruana Cayetana Heredia and as the former Chief of the Peruvian National Institute of Health. She is a member of the World Bank Disease Control Priorities-3 Advisory Committee.

Julie Gralow

The Jill Bennett Endowed Professor of Breast Medical Oncology and Professor of Global Health at the University of Washington School of Medicine, a Member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, and Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. Dr. Gralow has dedicated her life to fighting breast cancer. She is actively involved in clinical care, education, and research, and has led numerous local and national clinical trials related to breast cancer treatment, prevention, and survivorship. She has also launched several women’s cancer support organizations.

Stein Kassa

Professor of Palliative Medicine at the Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), National Cancer Director at the Norwegian Directorate for Health, Chair of the European Palliative Care Research Centre and Network. He has worked extensively to get palliative care research on the national and global agenda, and is a prolific researcher who has published more than 450 peer-reviewed articles and book chapters.

Richard Sullivan

Richard Sullivan is the founding Director of the King’s Health Partner’s Institute of Cancer Policy & Global Health and leading expert on global cancer policy and global health security. He is the former Clinical Director of Cancer Research UK. He has chaired several high-profile Lancet Commissions on delivering affordable cancer care in high-income countries, global cancer surgery, and cancer care in LMICs. He has a far-reaching international network through which he collaborates to design, implement and evaluate local, regional and global cancer policy.

Julio Frenk

Professor Julio Frenk, is a Mexican physician, scholar and renowned leader in global public health. He is the current President of the University of Miami, and former Dean of the Harvard TH Chan School of Public Health. Prof. Frenk was the founding-director of the National Institute of Public Health in Mexico, and served as the Secretary of Health in Mexico from 2000-06 where he led major health system reforms and introduced a comprehensive universal health coverage program, Seguro Popular. This expanded access to health care for over 55 million uninsured Mexicans. He is renowned for his work on health policy, global health governance, medical education, and health system reform.

Camilla Zimmerman

Dr. Camilla Zimmermann is Head of the Division of Palliative Care at the Princess Margaret Cancer Centre and the University Health Network, and a Senior Scientist at the Princess Margaret Cancer Centre Research Institute. She is also Professor of Medicine and Rose Family Chair in Supportive Care at the University of Toronto.

Dr. Zimmermann is internationally known for her research on palliative and supportive cancer care, particularly in the area of early palliative care. She has published more than 100 papers in peer-reviewed journals, and is co-editor of the textbook Supportive Oncology. Her research on early palliative care in patients with solid tumours and leukemia is funded by the Canadian Cancer Society and the Canadian Institutes for Health Research.

Dr. Zimmermann was awarded the William E. Rawls Prize by the Canadian Cancer Society for her research, which is focused on determining the best way to provide timely, integrated symptom management and supportive care for patients with cancer and their families.

Eduardo Cazap

Eduardo Cazap MD, PhD is an Argentinean medical oncologist with a longstanding clinical and scientific career in Argentina and Internationally.

Founder and first President of the Latin American & Caribbean Society of Medical Oncology (SLACOM) , Past- President of the International Union against Cancer (UICC) and Member of the Executive Committee of the National Cancer Institute of Argentina since 2010.

Published over 190 papers with main areas in global health, cancer control and prevention, breast and cervical cancer and independent clinical research.

He is one of the beginners of the concept of “Global Cancer Control” and in the year 2000 was signatory of the Charter of Paris against Cancer.

Dr. Cazap also serves as Chairman of the Executive Committee of the Breast Health Global Initiative (BHGI) and in 2011 was Co-chair of the Civil Society Taskforce to advise the President of the United Nations General Assembly on the 2011 United Nations High-Level Meeting on Non-communicable Diseases.

President of the UICC World Cancer Congress, Montreal, Canada, in 2012. Dr Cazap received in 2013 the Distinguished Achievement Award of the Conquer Cancer Foundation (USA) and bestowed as Fellow of the American Society of Clinical Oncology (FASCO).

Most recently he has been appointed as member of the Global Oncology Leadership Task Force, American Society of Clinical Oncology (ASCO) 2014-2016 and President of the Senologic International Society (SIS) 2017-2019

Dr Cazap participated as a Consultant in different projects and programs for WHO, PAHO, IARC, NCI-US, IAEA-PACT and other regional as well as international organizations.

Eduardo Cazap has a vast in-country and international experience and is a regular plenary speaker, chair or moderator at global cancer and health meetings as well as part of organizing major international conferences.

Carlo M. Nalin, Ph.D.

Carlo Nalin, Ph.D. is Global Head of Drug Assessment and Advocacy in Therapeutics Integrity & Established Medicines for Novartis Oncology.

Dr Nalin began his pharmaceutical career as a protein biochemist at Hoffmann-La Roche involved in drug discovery for treatment of HIV and infectious diseases. He joined the Sandoz Research Institute in 1993, and led drug discovery teams as a research laboratory head and as a group leader with several laboratory teams focused on targeted Oncology drugs. Following the merger that created Novartis, Dr. Nalin moved from research to the drug development organization where, over ten years, he led development teams for three early drug candidates in clinical trials and then for several drugs that during his tenure received additional drug approvals in cancer indications including Femara® for metastatic and adjuvant breast cancer and Glivec®, the breakthrough treatment for Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors and several other rare tumor types. Dr. Nalin assumed his current responsibilities in 2009.

Carlo received his bachelor degree in Biophysics from the University of Pennsylvania and holds a PhD in Biochemistry from the State University of New York Medical University at Syracuse. His postdoctoral trainings were performed at Cornell University and at the Roche Institute for Molecular Biology. He is the author of more than 30 research articles and book chapters and has presented his work at numerous international conferences.

Mary Gospodarowicz, MD FRCPC FRCR(Hon) FFRCSI(Hon)

Mary Gospodarowicz is Professor of Radiation Oncology at the University of Toronto, the Medical Director of the Princess Margaret Cancer Centre at the University Health Network, and the Regional Vice President of Cancer Care Ontario. She is past Chair of Radiation Oncology at the University of Toronto. She holds specialty certifications in internal medicine, radiation oncology, and medical oncology and her clinical practice involves lymphomas and genitourinary cancers. Her research focused on clinical trials evaluating radiation therapy, image-guided precision radiotherapy, and cancer survivorship. Her current interests include global cancer control, global access to radiotherapy, and quality cancer care.

Professor Gospodarowicz is Past-President of the Union for International Cancer Control (UICC). She proudly participates in the work of the Global Task Force on Cancer Care and Control of Harvard Global Equity Initiative and the HGEI-Lancet Commission on Global Access to Pain Control & Palliative Care. Under the auspices of UICC and Lancet Oncology, the Global Task Force on Radiotherapy produced a seminal report on ‘Expanding the global access to radiotherapy” that provided evidence for the demand, efficacy, and cost effectiveness of radiotherapy.

Prabhat Jha, OC, MD, DPhil, FCAHS

Professor Prabhat Jha is an Endowed Professor in Global Health and Epidemiology at the University of Toronto and Canada Research Chair at the Dalla Lana School of Public Health, and the founding Director of the Centre for Global Health Research. Professor Jha is a lead investigator of the Million Death Study in India, which quantifies the causes of premature mortality in over 2 million homes. His publications on tobacco control have enabled a global treaty now signed by over 180 countries. He founded the Statistical Alliance for Vital Events, which focuses on reliable measurement of premature mortality worldwide.

Earlier, Professor Jha served in senior roles at the World Health Organization and the World Bank. He was made an Officer of the Order of Canada in 2012. Professor Jha holds an M.D. from the University of Manitoba and a D.Phil. from Oxford University, where he studied as a Rhodes Scholar

Gail Turner

Gail Turner is Inuit, a beneficiary of the Labrador Inuit Land Claim, who retired in 2012 from the position of Director of Health Services for the Nunatsiavut Government, Northern Labrador. She holds a Bachelor of Nursing degree from Memorial University of Newfoundland, a Master’s of Adult Education from St. Francis Xavier University, and many additional certificates in health and administration through distance programs. Her early career was spent in acute care nursing in Ontario and the United Kingdom. For the last twenty- six years she has been working in Labrador with Inuit, Southern Inuit of NunatuKavut, settlers, First Nations, and since 2004 exclusively with the Inuit. She has presented on Inuit health at provincial, regional, national and international meetings and symposiums, including the World Cancer Congress in 2011. Her work has been focused in public health but she has also managed remote community clinics and continuing care. She is passionate about the North and the need for First Nations, Inuit and Métis to be heard and truly engaged in the planning of their health care and the promotion of optimal health. Her growing interest is in health equity and the pressing need for innovative and community based solutions for bringing health care service to the people. Gail is the Indigenous Director on the Board of the Canadian Partnership Against Cancer (CPAC). She is a recent recipient of the Labradorians of Distinction Award for services to health and community. As a senior she has a growing interest in senior wellness, access to appropriate home care and long- term care when needed and ageing in place.

Lisa Stevens, PhD

Dr. Stevens’ desire to facilitate and promote science is what brought her to the Office of the Director, NCI, in 2000. She joined the Center for Global Health (CGH) as the Deputy Director for Planning and Operations in 2012. In support of NCI, she has fostered collaborations, created decision-making tools, and overseen the development of strategic plans.

Since joining CGH, Lisa has focused on gathering input—both internal and external—to facilitate the development of the strategic priorities for the Center. As the Senior Lead of the International Global Cancer Control Program Lisa has worked with Ministries of Health and other multi-sectorial groups in all WHO Regions to include evidence-based policies in a cancer control and/or NCD control plans. In addition, Lisa co- founded the International Cancer Control Partnerships to organize multiple global partners working with stakeholders in the area of cancer control. This partnership has focused on collating published cancer control and NCD plans as well as other tools that individuals charged with developing, implementing, or evaluating national plans can utilize.

Prior to joining CGH, Dr. Stevens has worked on many strategic planning activities across NCI. She facilitated interactions among the NCI Divisions, Offices, and Centers, as well as other NIH Institutes and Centers. Dr. Stevens has guided the creation and communication of the long-range plan of the Institute, the yearly plan and budget request, and highlights of scientific progress.

Michael Sherar, PhD

President and Chief Executive Officer, Cancer Care Ontario
Dr. Michael Sherar is President and CEO of Cancer Care Ontario, a role he was appointed to in 2011. From 2006 to 2011, he was the provincial agency’s Vice-President, Planning and Regional Programs, leading the development of Regional Cancer Programs, including capital planning for cancer services across the province.

Dr. Sherar is an Affiliate Scientist at the Techna Institute University Health Network where he carries out research and development of minimally invasive thermal therapy technologies for cancer including radiofrequency ablation.

Dr. Sherar received a BA in Physics from Oxford University in 1985 and his PhD in Medical Biophysics from University of Toronto in 1989.

Chris Fosker, MBChB, BSc, MRCP, FRCR

Dr. Fosker is the Radiation Therapy Director and Radiation Oncologist at Bermuda Cancer and Health Centre in Bermuda, a Consultant Clinical Oncologist with Bermuda Hospitals Board, an affiliate of the Dana-Farber Cancer Institute and Consultant at the Brigham and Women’s Hospital in Boston.

Dr. Fosker was the clinical lead in the project that brought radiation therapy to the country of Bermuda for the first time. Bermuda Cancer and Health Centre has a clinical affiliation with Dana-Farber/ Brigham and Women’s Cancer Center for Radiation Therapy. As a not-for-profit organization, Bermuda Cancer and Health Centre seeks to provide equal access to all their clinical services including radiation therapy and currently subsidises all costs not covered by health insurance.

Dr. Fosker obtained his medical degree from the University of Leeds in the UK in 2003, and shortly after that went on to become a Member of the Royal College of Physicians (2006) and Fellow of the Royal College of Radiologists in the UK (2011). In 2012, he completed a Clinical Fellowship at the University of Toronto and was subsequently awarded the R.S. Bush Award for Academic Excellence as a Radiation Oncology Fellow.

Sir Michael Marmot

Sir Michael Marmot, has pioneered research into health inequalities and their causes for over 35 years. He was Chair of the Commission on Social Determinants of Health, set up by the WHO in 2005, led the longitudinal Whitehall Studies of health outcomes in British civil servants and authored the Marmot Review: Fair Society, Healthy Lives which estimated the staggering impact and cost of health inequities in Britain. He is currently the Director of the UCL Institute of Health Equity, and immediate past President of the World Medical Association. He was knighted by Queen Elizabeth II for services to Epidemiology and understanding health inequalities in 2000.

Cary Adams

CEO of the Union for International Cancer Control (UICC), where he leads global efforts in cancer advocacy, convening the cancer community (through World Cancer Day, the World Cancer Congress and the World Cancer Leaders’ Summit) and running significant global capacity building projects that address global cancer issues. He has served two terms as Chair of the NCD Alliance, a coalition of 2000 organisations working on non-communicable diseases.

David Watkins

David Watkins is a physician-scientist in the Departments of Medicine at the University of Washington and University of Cape Town, and he is a senior researcher with the Disease Control Priorities Network, and his scientific interest is in priority setting for health in low- and middle-income countries, with a particular interest on prevention and control of noncommunicable diseases.

Avram Denburg

Avram Denburg received his medical degree from McMaster University in 2006. He completed both a residency in paediatrics and a fellowship in haematology/oncology at The Hospital for Sick Children (SickKids). Denburg has a Master of Science in Health Policy, Planning and Financing from the London School of Economics and the London School of Hygiene and Tropical Medicine, pursued with the support of a Commonwealth Scholarship. He trained at Harvard University as a National Institutes of Health-funded Pediatric Scientist Development Program Fellow. Denburg is currently pursuing a PhD in health policy as a 2015 Trudeau Scholar and CIHR Fellow at the Centre for Health Economics and Policy Analysis at McMaster University.

Dr. Denburg’s research focuses on the political, ethical and economic dimensions of child health policy, in both local and global contexts. His doctoral research examines normative and methodological issues in the assessment of child health technologies, with specific focus on pharmaceutical policy and drug coverage decisions for children.

Charles K.N. Chan M.D., FRCPC, FCCP, FACP

Dr. Charlie Chan is the Interim President & CEO at University Health Network (UHN). Other leadership roles at UHN include Chief Medical Officer and Executive Vice President for Clinical Programs, Quality & Safety. He was appointed Professor of Medicine at the University of Toronto (U of T) in 2005. After receiving his M.D. and completing his Internal Medicine & Pulmonary Medicine training at U of T, Dr. Chan continued his clinical training at Yale University. He was also a Visiting Scholar at Yale University’s Robert Wood Johnson Clinical Scholars Program. Dr. Chan has served and chaired numerous national and international expert panels for respiratory condition treatment guidelines. Dr. Chan has also served as board members for several non-profit foundations.

Susan Henshall

After gaining a PhD in hepatitis, Dr. Henshall continued her research training at the University of London before returning to Australia where she led a translational cancer research laboratory at the Garvan Institute of Medical Research. Over the course of her career, she has completed a MPH and held appointments at the University of NSW and Georgetown University. In 2013, she founded the global health consultancy, Three Stories Consulting that works with organisations to make the best use of evidence for successful advocacy by creating resources and building capacity around global health issues with a focus on NCDs.

Doris Howell RN, PhD

Dr. Doris Howell, RN PhD, is the RBC Chair in Oncology Nursing Research and Education at the University Health Network and a Professor in the Lawrence S. Bloomberg Faculty of Nursing with a cross-appointment in the Institute of Health Policy, Management and Evaluation (IHPME). As a Senior Scientist in the Department of Psychosocial and Supportive Care, Ontario Cancer Institute and as an Affiliate Scientist with the ELLICSR Health, Wellness & Cancer Survivorship Centre, University Health Network, Dr. Howell conducts health intervention research testing the effects of personalized symptom and self-management support interventions in early survivorship on symptom burden, cancer morbidity and health recovery. She is the Co-Director of the Ontario Patient Reported Outcomes-Symptoms and Toxicity Research Unit (On-PROST) testing the implementation of Patient Reported Outcomes (PRO) in routine clinical practice on health outcomes.

Christine Campbell

Dr Christine Campbell is a Reader at the Usher Institute at the University of Edinburgh. She leads a programme of research in the interface of cancer and primary care. She has held positions as cancer co-lead for the Scottish School of Primary Care Cancer Programme, and until recently was chair of the Screening sub-group of the UK’s NCRI Primary Care Group. She sits on the Executive Group of Ca-PRI, the international cancer and primary research network. Recent and ongoing projects span the cancer journey from prevention through symptomatic diagnosis and survivorship, but with an emphasis on cancer screening and diagnosis (both within the UK and in sub-Saharan Africa), health disparities, and the role of policy in health system interventions in cancer.

Stephanie Lheureux

Stephanie Lheureux is a Clinician Investigator in the Bras Drug Development Program, Staff Medical Oncologist and Gynecology Site Leader at Princess Margaret Cancer Centre. She is also an Assistant Professor at the University of Toronto.

Following her Medical Degree and specialization in Medical Oncology (University of Caen, France) she was recruited as an Assistant Professor at the Academic Cancer Center of Caen (Normandy, France), where her practice combined research and clinical care in gynecologic cancers. Shortly thereafter, Dr. Lheureux received her PhD with merit for preclinical evaluation of new targeted therapies and drug resistance mechanisms in ovarian cancer. She worked on new treatment to overcome chemoresistance in ovarian cancer models including an imaging component. Based on her project findings, she designed a phase II clinical trial of with integrated correlatives studies in platinum-resistant ovarian cancer led by GINECO (NCT#02591095), the French arm of the Gynaecologic Cancer InterGroup.

Jennifer Jones

Dr. Jennifer Jones has been appointed the new Butterfield/Drew Chair in Cancer Survivorship Research at Princess Margaret Cancer Centre for a five-year term.

Dr. Jones is a Senior Scientist and the Director of Cancer Rehabilitation and Survivorship Program and Associate Director of the Centre for Health Wellness and Cancer Survivorship (ELLICSR) at Princess Margaret Cancer Centre. She is also an Associate Professor at the University of Toronto.

She has produced scholarly and professional work based on the topic of translational research to inform clinical survivorship care. Her work focuses on examining new approaches to predict, prevent, and manage long-term adverse effects of cancer and its treatment.

In addition to her work in cancer effects and treatment, Dr. Jones has experience evaluating innovative models of follow-up care and support for the increasing number of cancer survivors.

Dr. Jones has also worked in implementation research, which focuses on translating evidence to clinical practices by developing integrated knowledge of translation models and education.

Danielle Rodin

Danielle Rodin, M.D., M.P.H., F.R.C.P.C., is a radiation oncologist at Dana Farber/Brigham and Women’s Cancer Center, the 2017-2018 fellow of the Canadian Association of Radiation Oncology, and The Commonwealth Fund’s Harkness Fellow in Health Care Policy and Practice. She completed her M.D. and postgraduate specialty training at the University of Toronto, and M.P.H. from Harvard University. She is now undertaking her fellowship in the Department of Health Policy and Management at the Harvard T. H. Chan School of Public Health, where she is identifying approaches to enhance the utilization of value-based cancer care. With that aim, she is analyzing variation in the treatment patterns and costs of specific clinical care pathways for prostate cancer, and the impact of clinical practice guidelines on the use of low-value cancer services for prostate, breast, and hematologic malignancies. Dr. Rodin’s work has been published in Lancet Oncology, Lancet Global Health, and numerous other peer-reviewed journals.

Linda Rabeneck

As the Vice-President, Prevention and Cancer Control, Dr. Linda Rabeneck oversees Cancer Care Ontario’s prevention, screening, research and surveillance programs.

Dr. Rabeneck is a gastroenterologist and clinician scientist. She is Professor of Medicine, Professor of Health Policy, Management and Evaluation, and Professor, Dalla Lana School of Public Health at the University of Toronto and Senior Scientist at the Institute for Clinical Evaluative Sciences (ICES) in Toronto. She is a Master of the American College of Gastroenterology and President-Elect of the Canadian Academy of Health Sciences.

Dr. Rabeneck received her medical degree from the University of British Columbia (UBC). She completed post-graduate training in internal medicine and gastroenterology at the UBC and the University of Toronto. She received her Master’s degree in Public Health from Yale University, where she trained as a Robert Wood Johnson Clinical Scholar. Dr. Rabeneck previously served as Director of the Division of Gastroenterology at the University of Toronto, and Regional Vice President, Cancer Care Ontario and Chief of the Odette Cancer Centre at Sunnybrook Health Sciences Centre.

Dr. Rabeneck played a leadership role in launching ColonCancerCheck in Ontario, Canada’s first organized, province-wide colorectal cancer screening program. She leads an active research program focusing on the quality and effectiveness of colorectal cancer screening, and has authored greater than 200 peer reviewed publications. Dr. Rabeneck is Chair of the World Endoscopy Organization (WEO) Colorectal Cancer Screening Committee, which holds international fora to discuss new information on colorectal cancer screening and promote the implementation of CRC screening.

Pam Tobin

Pam Tobin, Director of First Nations, Inuit and Métis Strategy Implementation at the Canadian Partnership Against Cancer.

Pam is an adopted member of the Takla Lake First Nation and sits with the Beaver Clan at Potlatch. She was given this honour in recognition for environmental health work she has done in and around the traditional territory of Tse Keh Nay in northern British Columbia. She has worked extensively with First Nations, Inuit and Métis throughout Canada and has also worked with Indigenous populations in Guatemala and Russia. In her role at the Partnership, is responsible for working with Indigenous partners and stakeholders to improve the cancer journey and to close the gaps in cancer and control in all provinces and territories.

Pam previously served as Director, Screening and Early Detection at the Partnership. She was responsible for collaborating with the national breast, colorectal, cervical and lung networks to improve the quality of and participation in organized screening programs. Prior to joining the Partnership, Pam was the Director, Regional Operations for the BC Cancer Agency Centre for the North. As part of the senior leadership team she led the integration of all clinical programs between the regional health authority and the BC Cancer Agency to improve access to care to rural, remote and isolated communities. Further, she led the day to day operations of the cancer centre.

Pam has an undergraduate degree in Anthropology and an Interdisciplinary Master’s Degree with a focus on First Nations Food Security from the University of Northern British Columbia. She also holds a graduate certificate in Project Management from Royal Roads University.

Usman Aslam, MPH,

Group Manager, Aboriginal Cancer Control Unit, Prevention and Cancer Control Department, Cancer Care Ontario.

Usman supported the development and implementation of Cancer Care Ontario's Aboriginal Cancer Strategies since 2012. Prior to joining the Aboriginal Cancer Control Unit, Usman led several projects in Cancer Screening at Cancer Care Ontario and held posts at the Cardiac Care Network of Ontario and the World Health Organization.

Bronwyn King

Dr. Bronwyn King is an Australian oncologist and founder and CEO of Tobacco Free Portfolios, a not-for-profit organisation that collaborates with the world’s largest financial organisations to drive global change towards tobacco-free finance.

Bronwyn started her medical career working on the lung cancer unit at the Peter MacCallum Cancer Centre in Melbourne. The devastating impact of tobacco on her patients left a deep impression. Years later, Bronwyn discovered her unwitting investment in tobacco companies through her super fund and felt obliged to try to bridge the gap between the health and finance sectors.

Tobacco-free finance policies have since been implemented by more than 40 Australian superannuation funds as well as Sovereign Wealth funds, banks, insurers and fund managers in ten countries, including BNP Paribas, AXA and Australian Super. More than AU$12 Billion away from investment in tobacco.

A former elite swimmer who represented Australia and for ten years worked as Team Doctor for the Australian Swimming Team, Bronwyn is also actively involved in a range of community initiatives. She is the Tobacco Control Ambassador for Cancer Council Australia, an Australia Day Ambassador, an Ambassador for Big Brothers Big Sisters Australia and a fellow of Leadership Victoria’s Williamson Community Leadership Program.

In 2013 she received the President’s Award for Tobacco Control from the Thoracic Society of Australia and New Zealand.

In 2014 she was listed as one of the Westpac/Australian Financial Review 100 Women on Influence.

In 2015 Bronwyn was awarded the VicHealth Award for Preventing Tobacco Use.

In 2016 she received the Dr Bob Elphick medal for tobacco control from the Australian Council on Smoking and Health.

In 2017 she was made the Inaugural Distinguished Fellow in a joint initiative between Kings' College London and the University of Melbourne, she became a Diplomat of the Global Charter of the World Association of Public Health Federations, was made a 2017 VicHealth Champion and delivered a TEDx Sydney presentation.

Wendy Lam

Dr. Wendy WT Lam is currently Associate Professor at the School of Public Health, as well as an adjunct Associate Professor at the School of Nursing, The University of Hong Kong. She is the head of the Division of Behavioural Sciences. She obtained her B.Sc (Nursing) from Queen’s University, Canada, then attended the University of Toronto obtaining her M.Sc in Nursing. She completed her Ph.D. specialized in Psycho-oncology from the University of Hong Kong. She was awarded the 2007 Hiroomi Kawano Young Investigator Award by the International Psycho-Oncology Society for her work on Chinese women with breast cancer. She is an active contributor in International Psycho-oncology Society, being a board of director and a chairman of the Liaison Committee. Her research interests focus on psychosocial adaptation patterns and service optimization in cancer patients.

Brenda Kostelecky, PhD

Lead for Cancer Control Planning and Policy – CGH, NCI

Dr. Brenda Kostelecky is the lead for the NCI Center for Global Health’s Cancer Control Planning and Policy team and manages NCI’s international cancer control planning and implementation initiatives. She has several years’ experience in science policy and strategic planning at NCI and has led development of the Cancer Control Leadership Forum Program with regional Forums developed that include the Middle East, Southeast Asia, the Caribbean, Latin America, and Central Asia. Dr. Kostelecky also played an instrumental role in creation and expansion of the International Cancer Control Partnership, a coalition of international organizations supporting national cancer control planning and implementation efforts that includes the Union for International Cancer Control, the World Health Organization, the International Agency for Research on Cancer, the American Cancer Society, the Centers for Disease Control and Prevention, the American Society of Clinical Oncology, and many other partners.

Dr. Kostelecky received her PhD in Molecular Biology from University College London and conducted her graduate research at Cancer Research UK focusing on structural determination of cancer-related cell signaling proteins, their binding partners, and targeted small-molecule drug candidates. She spent several additional years developing and conducting biological research projects at the European Molecular Biology Laboratory in Germany, the University of Colorado, and the U.S. National Institutes of Health. Dr. Kostelecky continued her training through the American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellowship, a fellowship specifically designed to train scientists in policymaking and implementation while contributing their knowledge and analytical skills to U.S. government agencies.

Jordan Jarvis

Jordan Jarvis is a Doctor of Public Health candidate at the London School of Hygiene and Tropical Medicine, focused on policy research to improve equitable access to care for cancer and other non-communicable diseases (NCDs) across low-income and marginalized populations. For over 3 years, Jordan served as the Executive Director of the Young Professionals Chronic Disease Network (YP-CDN), a global advocacy network and nonprofit organization with over 7,000 members in over 150 countries. As a YP-CDN Board member, Jordan continues to support global advocacy initiatives and advocacy capacity building for NCDs, with a particular focus in East Africa. Previously, Jordan completed a postgraduate research fellowship at the Harvard Global Equity Initiative (HGEI) at Harvard Medical School, and worked for Amref Health Africa conducting research and advocacy for cervical cancer and human resources for health in Kenya, the International Agency for Research on Cancer/WHO in France, and on cancer policy at the World Health Organization. She holds a BSc (Hons) in Biology from Western University, an MSc in Medical Biophysics from the University of Toronto, and completed a certificate in Global Health Policy with Duke University’s Sanford School of Public Policy’s Global Health Fellows Program. She is currently a World Heart Federation Emerging Leader and completed the CEO Training Program through the Union for International Cancer Control in 2016.

Terry Sullivan

Terrence Sullivan is a behavioral scientist, Professor and Senior Fellow at the Institute for Health Policy, Management & Evaluation, Dala Lana School of Public Health, University of Toronto and adjunct professor in the Department of Oncology at McGill University. His research interests span Cancer Control, Quality and Performance Strategies, Disability Policy and Public/Private Issues in Health Policy.

In governance roles he chairs the board of the Canadian Agency for Drugs and Technologies in Health, the quality committee of the Hospital for Sick Children, the governance and nominations committee of Exactis Innovation (a federal NCE) and is a member of the board of Vector AI. From 2001 to March 2011 he occupied leadership positions at Cancer Care Ontario (CCO), the final seven years as President and CEO during which period organization transformed its business model to a cancer control organization with a strong focus on performance measurement, reporting and improvement of cancer services. Founding president of the Institute for Work & Health (1993-2001), he previously played senior roles in the Ontario Ministries of Health, Cabinet Office and as Assistant Deputy Minister, Constitutional Affairs and Federal-Provincial Relations during the Charlottetown negotiations. He served two successive First Ministers of Ontario as Executive Director of the Premier's Council on Health Strategy.

Mei Ling Yap

Mei Ling Yap is a staff specialist radiation oncologist and director of training at Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia. Mei Ling undertook her radiation oncology speciality training in Australia and Singapore from 2007-2011. She then undertook a clinical research fellowship at Princess Margaret Cancer Centre, Toronto from 2011-2013. Mei Ling was a member of the Global Task Force in Radiotherapy on Cancer Control (GTFRCC) and co-author of the Lancet Oncology Commission. She now sits on the steering committee of the Global Impact of Radiotherapy on Oncology (GIRO) project. Mei Ling is co-chair of the Asia Pacific Radiation Oncology Special Interest Group (APROSIG-RANZCR), which supports LMIC radiotherapy departments in the Asia-Pacific through a bilateral exchange, training and education. She also co-runs GlobalRT, an online platform advocating for equitable access to radiotherapy globally. Mei Ling was selected as a UICC ‘Young Cancer Leader’ in 2015. Mei Ling holds a conjoint senior lecturer appointment with the University of Western Sydney and University of New South Wales and an adjunct senior lecturer appointment with the University of Sydney. Mei Ling is currently undertaking a PhD with the University of NSW, Cancer Council NSW and Collaboration for Cancer Outcomes Research and Evaluation (CCORE), exploring the socio-demographic factors which influence radiotherapy utilization in Australia.

Rachel Spitzer

Rachel Spitzer is currently the Director AMPATH at the University of Toronto. She is also Associate Professor and Vice Chair, Global Women’s Health at the University of Toronto, Department of Obstetrics and Gynecology; and staff physician at Mount Sinai Hospital.

Anna Goldenberg

Anna Goldenberg is a Scientist in Genetics and Genome Biology program at the SickKids Research Institute, an Assistant Professor in the Department of Computer Science at the University of Toronto, cross appointed in the Department of Statistics, faculty member at Vector and a fellow at the Canadian Institute for Advanced Research (CIFAR), Child and Brain Development group. Dr Goldenberg trained in machine learning and statistics at Carnegie Mellon University, with a post-doctoral focus in computational biology and medicine. She is an expert in developing machine learning approaches for biological data, network methods and most recently, data integration of omics and clinical data. The current focus of her lab is on developing methods that capture heterogeneity and identify disease mechanisms in complex human diseases. Her translational focus is on methods that efficiently combine many types of patient measurements to refine diagnosis, improve prognosis and personalise drug response prediction for patients with complex human diseases. She was recently awarded an Early Researcher Award from the Ministry of Research and Innovation and a Canada Research Chair in Computational Medicine.

Sue Horton

Sue Horton became interested in working on health and economics while spending a summer during grad school working for the World Bank, which was newly interested in lending for health. She then spent six months at the International Centre for Diarrheal Disease Research in Bangladesh while writing my thesis. That led to a lot of varied projects. She worked or taught in about 25 low and middle income countries, on topics ranging from labour markets, women's participation, benefits and costs of micronutrient interventions, and currently costs and benefits of breastfeeding, cost and cost-effectiveness of cancer interventions, and disease control priorities in low and middle income countries. Sue Horton has also worked on research projects with the World Bank, FAO, WHO, UNICEF, Copenhagen Consensus, among others, and currently the Disease Control Priorities project.

Xiaolin Wei

Dr. Xiaolin Wei is the Faculty’s first Associate Professor of Health Systems and Clinical Public Health in Asia — a shared core faculty position with the Dalla Lana School of Public Health’s Division of Clinical Public Health and the Institute of Health Policy, Management and Evaluation — as of April 8, 2016.

Wei is an internationally-recognized leader in healthcare and health policy with a focus on primary care reform and tuberculosis control. He is also an IHPME alumnus, holder of the 2004 Dr. Ted Goldberg Scholarship and he participated in the School’s Global Health Summit in November 2014 by addressing the question, what is the gold standard for health systems?

Wei has held visiting professorships at the Nuffield Centre of International Health and Development at the University of Leeds, UK, where he is also a Fellow of the Faculty of Public Health. Wei is also a technical advisor to the World Health Organization on tuberculosis and influenza and the secretary-general and executive board member of the International Union Against Tuberculosis and Lung Disease.

His major research interests include primary care reforms and policy evaluation, and health service delivery studies in tuberculosis and cardiovascular disease control, mostly in primary care settings.

In this role, Wei will lead joint initiatives between DLSPH and partners in Asia to establish a framework in which to generate evidence on best practices related to primary care and primary care systems. One key research area will be to create models for training general practitioners, given China’s goal to train 300,000 general practitioners in the next decade.

Michael Milosevic

Michael Milosevic is a radiation oncologist in the Radiation Medicine Program, Princess Margaret Cancer Centre and University Health Network, Toronto, Canada. He is a Professor and the Vice-Chair of Research in the Department of Radiation Oncology at the University of Toronto, a past-President of the Canadian Association of Radiation Oncology (CARO) and the Chair of the Canadian Partnership for Quality in Radiotherapy (CPQR). Dr. Milosevic’s clinical practice is in the management of gynecological cancers. His research is focused in two main areas: high precision, MR-guided external beam radiotherapy and brachytherapy; and biological targeting of tumor hypoxia and immune-mediated radiation treatment resistance. He is committed to building radiation treatment capacity in developing parts of the world where gynecological cancers are among the most common and debilitating diseases.

Barry Rosen

Dr Rosen graduated from medical school at The University of Western Ontario in London Ontario. He completed his obstetrics and gynecology residency at McMaster University in Hamilton and his Gynecologic oncology fellowship at the University of Toronto.

After completing his fellowship he worked at both Princess Margaret Hospital and Toronto General Hospitals in Toronto. In 2002 he was appointed the Head of Gynecologic Oncology at the University of Toronto and Head of Gynecologic Oncology at University Health Network. Dr Rosen was on staff at Princess Margaret Hospital from 1985 to 2015.

He has published over 140 peer reviewed papers and has given a similar number of peer reviewed presentations. A main focus of research has been in hereditary ovarian cancer. In addition he has established clinical databases in gynecologic oncology at UHN and has worked with CPAC to promote the strategies to collect point of care clinical data.

Dr Rosen developed an interest in global health 10 years ago during a visit to Eldoret Kenya where he spent 5 weeks working with the local gynecologists. During a second visit he taught two gynecologists how to do surgery for cervix cancer and subsequently in collaboration with Moi University he helped develop and initiate a gynecologic oncology fellowship training program in Kenya, the first of its kind in Sub-Saharan Africa outside of South Africa. This program has graduated 5 fellows to date and three more are in training.

He recently moved to Michigan in June 2015 and is Section Head of Gynecologic Oncology for Beaumont Health and Professor at Oakland University William Beaumont School of Medicine.

Adalsteinn Brown

Adalsteinn (Steini) Brown is the Interim Dean of the Dalla Lana School of Public Health at the University of Toronto and the Dalla Lana Chair of Public Health Policy at the University. Past roles include senior leadership roles in policy and strategy within the Ontario Government, founding roles in start-up companies, and extensive work on performance measurement. He received his undergraduate degree in government from Harvard University and his doctorate from the University of Oxford, where he was a Rhodes Scholar.

Nazik Hammad

Dr. Hammad is a medical oncologist at the Department of Oncology, Queen’s University, Canada, where she is the program director of the medical oncology training program. She is a member of the Canadian Royal College of Physicians and Surgeons Medical Oncology subspecialty Committee.

She received her MBBS qualification from the University of Khartoum, M.Sc. Immunology from University of Toronto, and Master in Medical Education (MEHP) from Johns Hopkins University. She completed internal medicine residency and haematology oncology Fellowship at Wayne State University.

Her areas of expertise in medical education include health professions education in LMICs, training program development and evaluation; competency-based medical education (CBME), accreditation, curriculum development, learner assessment, mentoring and innovations in education to address faculty shortages and harness South-South and South-North partnerships in education. She teaches regularly at the Clinical Oncology Training Program in Khartoum. She is the North America vice president for the African Organization in Research and Training in Cancer (AORTIC) and has served as interim chair of the AORTIC Education and Training Committee. She also serves as a virtual mentor for ASCO.

Her research in medical education focuses on assessment and feedback, accreditation and CBME in low resource-settings in addition to cross culture and comparative research in medical education

Michael Barton

Michael Barton OAM is Professor of Radiation Oncology at UNSW, and Research Director of the Collaboration for Cancer Outcomes Research and Evaluation (CCORE) and the Ingham Institute for Applied Medical Research at Liverpool Hospital. He is the Principal of the Cancer Research Theme of the Faculty of Medicine UNSW.

He has chaired reviews of cancer services throughout Australia and overseas including; the Victorian Cancer Services Framework Report, the Papua New Guinea Cancer Services Report, the Review of Cancer Services in New South Wales in 2004, the feasibility study of radiotherapy in the Northern Territory and a review of cancer services in Western Australia. He chaired the expert advisory committee examining the feasibility of establishing a radiotherapy service in North West Tasmania.

Eva Grunfeld

Dr. Eva Grunfeld is a leader in cancer health services and outcomes research. Her research focuses on evaluation and knowledge translation of cancer health services, covering the entire spectrum of cancer control activities. She is internationally recognized for research on cancer survivorship.

Dr. Grunfeld uses a mixed-methods approach including randomized controlled trials, qualitative research and outcomes research. Knowledge translation is an integral part of all her research activities. She has conducted several multi-centre RCTs on cancer survivorship which has influenced clinical practice guidelines and policies internationally.

Dr. Grunfeld holds many peer-review grants as Principal Investigator and has served on many committees to further the goals of cancer control in Canada and internationally. She obtained her medical degree from McMaster University and doctoral degree in cancer epidemiology from Oxford University.

Nir Hacohen

Nir Hacohen is an immunologist and geneticist focused on developing and applying unbiased methods to understand the mammalian immune response.

His group is focused on several inter-related areas, including: (i) viral and bacterial sensing in dendritic cells, the sentinel cells of the immune system; (ii) detection of self vs. non-self by the innate immune system; (iii) genetic basis for the observed variation in immunity across the human population, with an emphasis on tumor immunity and autoimmunity; and (iv) novel and personalized immunotherapeutics.

He is co-director of the Broad Cell Circuits Program, co-director of the Broad Center for Cell Circuits, and a founding PI of the Broad Genetic Perturbation Platform and Functional Genomics Consortium.

Hacohen received an AB in physics from Harvard University and a PhD in biochemistry from Stanford University. After starting his own group as a Whitehead Institute Fellow, he moved to the Broad Institute and joined the faculties of Harvard Medical School and Massachusetts General Hospital.

Aisha Lofters

Aisha Lofters is a family physician with the St. Michael’s Hospital Academic Family Health Team and scientist with the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is an assistant professor at the University of Toronto in the Department of Family and Community Medicine and adjunct scientist at the Institute for Clinical Evaluative Sciences. She currently holds a Career Development Award in Prevention from the Canadian Cancer Society Research Institute. Her research interests include cancer screening, immigrant health and health equity, using a broad range of methods including secondary database analysis and community-based participatory research.

Diana Sarfati

Professor Diana Sarfati (MBChB, MPH, PhD, FNZCPHM) is a public health physician and epidemiologist with a particular interest in the interface between public health and clinical medicine. She is co-Head of the Department of Public Health and the Director of the Cancer and Chronic Conditions (C3) research group.

Professor Sarfati has a range of research interests relating to cancer, long term conditions and health services. She has led a large body of work relating to ethnic disparities in cancer outcomes. This work has resulted in the identification of key patient and health system factors that influence cancer survival. This work has been used extensively by health policy makers, clinicians and other researchers to develop policies and practices that aim to reduce inequities in cancer outcomes.

Trevor Young

Professor Trevor Young is Dean of the University of Toronto’s Faculty of Medicine and Vice Provost, Relations with Health Care Institutions.

Prof. Young is a clinician-scientist who studies the molecular basis of bipolar disorder and its treatment. He has published more than 200 peer-reviewed journal articles and has held more than 35 peer-reviewed grants. Prof. Young and his lab focused on the processes that lead to long-term changes in brain structure and function in patients with bipolar disorder, and how mood-stabilizing drugs can alter those changes. Prof. Young has supervised more than 30 research and clinical trainees.

Since January 1, 2015, Prof. Young has been Dean of Canada’s largest Faculty of Medicine, with more than 8,000 faculty members and 6,900 students enrolled in undergraduate medicine, postgraduate medicine, radiation sciences, and professional and doctoral graduate programs. As Vice Provost, he is responsible for the University’s partnership with nine fully affiliated hospitals and 18 community-affiliated hospitals and health facilities. The Faculty of Medicine and the fully affiliated hospitals are also a thriving research enterprise — one of the largest in North America — that includes one-fifth of all health and biomedical Canada Research Chairs and has attracted $804 million in research funding (2013-14). In 2015, the National Taiwan University Ranking placed U of T first in Canada and third in the world; the Faculty of Medicine was also third in the world in the sub-category of clinical medicine.

Jennifer Chan

Jennifer Chan is Vice President, Policy and External Affairs, at Merck Canada Inc. and is responsible for the company’s team of government relations and public affairs specialists. Prior to this role, she held the position of Vice President, Policy and Communications at Merck Canada since December 2011. A native of Montreal, Jennifer began her career in academic research before joining Schering-Plough in 1993 as a Clinical Research Associate.

Jennifer is a member of the Board of Directors of the Institute of Health Economics in Alberta, as well as the Quebec Consortium for Drug Discovery and the Quebec Network for Personalized Health Care. She is co-chair of the Canadian Biosimilars Forum and has served as a Merck for Mothers ambassador in Canada since the program was launched in 2011. Jennifer holds a Bachelor of Science degree in physiology and a Master of Science degree in pharmacology and therapeutics, both from McGill University in Montreal.